U.S. SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549


                                   FORM 10-QSB

(MARK ONE)

[X]      Quarterly Report Pursuant to Section 13 or 15(d) of Securities Exchange
         Act of 1934

                For the quarterly period ended SEPTEMBER 30, 2004

[ ]      Transition report under Section 13 or 15(d) of the Securities Exchange
         Act of 1934

                For the transition period from _______ to _______

                          Commission File No. 000-31889

                               BIO-ONE CORPORATION
                               -------------------
                 (Name of Small Business Issuer in Its Charter)
<TABLE>
<CAPTION>

<S>                                                                                         <C>
                                NEVADA                                                      65-0815746
                                ------                                                      ----------
    (State or Other Jurisdiction of Incorporation or Organization)             (I.R.S. Employer Identification No.)


       1630 WINTER SPRINGS BOULEVARD, WINTER SPRINGS, FLORIDA                                  32708
       -------------------------------------------------------                                 -----
               (Address of Principal Executive Offices)                                     (Zip Code)

</TABLE>

                                 (407) 977-1005
                                 --------------
                (Issuer's Telephone Number, Including Area Code)

         Check whether the issuer: (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months, and (2) has
been subject to such filing requirements for the past 90 days.  Yes [ ]  No [X]

         There were 165,003,173 shares of common stock outstanding as of
November 1, 2004.

<PAGE>

                               BIO-ONE CORPORATION


                                      INDEX

                                                                        PAGE
                                                                       NUMBER

PART 1.  FINANCIAL INFORMATION

  Item 1. Financial Statements

          Balance Sheets
            September 30, 2004 (Unaudited)
              and December 31, 2003                                       3

          Statements of Operations
            Three months and nine months ended
              September 30, 2004 (Unaudited) and
              September 30, 2003 (Unaudited)                              4

          Statements of Cash Flows
            Nine months ended
              September 30, 2004 (Unaudited) and
              September 30, 2003 (Unaudited)                              5

          Notes to Financial Statements (Unaudited)                       6

  Item 2. Management's Discussion and Analysis of
          Financial Condition and Results of Operations                   7

PART II.  OTHER INFORMATION                                              25


                                       2
<PAGE>

                                     PART I


                              FINANCIAL INFORMATION


ITEM 1.  FINANCIAL STATEMENTS


                                 BIO-CORPORATION

                                 BALANCE SHEETS
<TABLE>
<CAPTION>

                                     ASSETS
                                     ------
                                                                    SEPTEMBER 30,
                                                                        2004        DECEMBER 31,
                                                                    (UNAUDITED)        2003
                                                                   ------------    ------------
<S>                                                                <C>                  <C>
Current assets:
    Cash and cash equivalents                                      $  1,200,198         210,021
    Accounts receivable                                               4,747,821          16,652
    Inventory                                                        10,257,577          23,537
    Prepaid expense                                                     485,523          35,437
                                                                   ------------    ------------
         Total current assets                                        16,691,119         285,647
     Property and equipment, at cost, net of accumulated
        depreciation and amortization                                 8,559,316          38,003

         Deposits and other assets                                      961,019         152,276
         Loan commitment fees, net                                    1,770,400         150,000
         Goodwill                                                    24,280,150              --
                                                                   ------------    ------------
Total assets                                                       $ 52,262,004         625,926
                                                                   ============    ============

                      LIABILITIES AND SHAREHOLDERS' EQUITY
                      ------------------------------------
Current liabilities:

     Accounts payable and accrued expenses                         $  6,205,132         184,420

     Current installments of note payable                             7,687,094         574,502

     Convertible debentures                                          10,800,000              --
                                                                   ------------    ------------

         Total current liabilities                                   24,692,226         758,922
                                                                   ------------    ------------


Notes payable, less current installments                             14,821,622              --

Minority interest                                                       660,000              --
Shareholders' equity:
     Common stock - $.001 par value, authorized 500 million
         shares; issued 165,003,173 shares and 44,238,915 shares        165,003          44,238

     Preferred stock - $.001 par value, authorized 10,000,000
         shares; issued 2,090,000 shares                              4,100,000              --


     Additional paid in capital                                      16,949,633       3,081,750

     Accumulated deficit                                             (9,126,480)     (3,258,984)
                                                                   ------------    ------------

Total shareholders' equity                                           12,088,156        (132,996)
                                                                   ------------    ------------
                                                                   $ 52,262,004         625,926
                                                                   ============    ============
</TABLE>

See accompanying notes to financial statements.

                                       3
<PAGE>

                               BIO-ONE CORPORATION

                            STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
                                         Three Months Ended                 Nine Months Ended
                                            September 30,                     September 30,
                                         2004            2003              2004            2003
                                     (UNAUDITED)      (UNAUDITED)       (UNAUDITED)     (UNAUDITED)
                                    -------------    -------------    -------------    -------------
<S>                                 <C>                     <C>          <C>                  <C>
Revenues:

  Net sales                         $  10,467,162           20,220       26,068,340           20,220
                                    -------------    -------------    -------------    -------------

Costs and expenses:

  Cost of goods sold                    8,245,298            6,904       19,684,545            6,904
  Selling, general and
administrative                          1,282,870          375,731        4,336,079          691,659
                                    -------------    -------------    -------------    -------------

                                        9,528,168          382,635       24,020,624          698,563
                                    -------------    -------------    -------------    -------------


Operating income (loss)                   938,994         (362,415)       2,047,716         (678,343)

Non-operating revenue (expense):

  Depreciation  and amortization       (1,273,958)              --       (2,256,958)              --

  Interest expense                       (645,039)          (4,783)      (5,484,841)         (12,782)
                                    -------------    -------------    -------------    -------------

      Income (loss) before income
      taxes and minority interest        (980,003)        (367,198)      (5,694,083)        (691,125)


Minority interest                        (285,000)              --         (660,000)              --

Provision for income taxes                     --               --               --               --
                                    -------------    -------------    -------------    -------------

     Net loss                       $  (1,265,003)        (367,198)      (6,354,083)        (691,125)
                                    =============    =============    =============    =============


Basic loss per share                $       (0.01)           (0.01)           (0.08)           (0.02)
                                    =============    =============    =============    =============


Diluted loss per share              $       (0.01)           (0.01)           (0.08)           (0.02)
                                    =============    =============    =============    =============

Weighted average number of shares
outstanding                           123,220,514       41,421,450       83,070,780       33,899,201
                                    =============    =============    =============    =============
</TABLE>

         See accompanying notes to financial statements.

                                       4
<PAGE>

                                 BIO CORPORATION

                             STATEMENT OF CASH FLOWS
<TABLE>
<CAPTION>

                                                                                Nine Months Ended
                                                                                     March 31,
                                                                               2004            2003
                                                                            (UNAUDITED)     (UNAUDITED)
                                                                           ------------    ------------
<S>                                                                        <C>                 <C>
Cash flows from operating activities:                                      $ (6,527,496)       (691,125)
   Net loss
   Adjustments to reconcile net income to net cash provide by
    operating activities:
     Stock issued for services                                                       --          27,300
     Depreciation and amortization                                            2,256,958           5,990
     Value for beneficial conversion feature                                  4,560,000              --
      Changes in operating assets and liabilities, net of acquisitions:
      Account receivable                                                      1,233,382              --
      Inventories                                                                54,713         (14,109)
      Prepaid expense                                                           (62,368)             --
      Accounts payable and accrued expenses                                      59,088        (160,924)
      Deposits                                                                 (807,291)        (31,389)
                                                                           ------------    ------------
      Net cash used in operating activities                                     766,986        (864,257)
                                                                           ------------    ------------
Cash flows from investing activities:
   Purchase of property and equipment                                        (1,461,809)         (8,240)
   Cash paid for acquisitions                                               (15,800,000)             --
                                                                           ------------    ------------
         Net cash used in investing activities                              (17,261,809)         (8,240)
                                                                           ------------    ------------
Cash flows from financing activities:
   Proceeds from sale of common stock                                           485,000       1,278,257
   Proceeds (repayments) of note payable, stockholder                                --         (67,800)
   Proceeds from debentures                                                  14,500,000              --
   Proceeds from notes payable                                                5,000,000              --
   Payments for loan financing cost                                          (2,500,000)             --
                                                                           ------------    ------------
     Net cash provided by financing activities                               17,485,000       1,210,457
                                                                           ------------    ------------
     (Decrease) increase in cash and cash equivalents                           990,177         337,960

Cash and cash equivalents - beginning of period                                 210,021          14,742
                                                                           ------------    ------------
Cash and cash equivalents - end of period                                  $  1,200,198         352,702
                                                                           ============    ============

Supplemental disclosure of non cash financing and investing activities:

   During the first quarter of 2004, $3,000,000 of notes payable
       were Converted into common stock at approximately $.24 per share

   During the third quarter of 2004, $4,200,000 of notes payable
       were Converted into 64,821,300 shares of common stock

Supplemental disclosure of noncash investing activities:
   Fair value of assets acquired                                           $         --          99,387
   Liabilities assumed                                                               --              --
   Cash acquired                                                                     --              --
</TABLE>

See accompanying notes to financial statements


                                       5
<PAGE>

                               BIO-ONE CORPORATION

                        I. NOTES TO FINANCIAL STATEMENTS



                               BIO-ONE CORPORATION


(1)      PRESENTATION OF UNAUDITED FINANCIAL STATEMENTS
         ----------------------------------------------

         The unaudited financial statements have been prepared in accordance
with rules of the Securities and Exchange Commission and, therefore, do not
include all information and footnotes necessary for a fair presentation of
financial position, results of operations and cash flows, in conformity with
generally accepted accounting principles. The information furnished, in the
opinion of management, reflects all adjustments (consisting only of normal
recurring accruals) necessary to present fairly the financial position as of
September 30, 2004 and results of operations and cash flows for the nine-month
periods ended September 30, 2004 and 2003. The results of operations are not
necessarily indicative of results which may be expected for any other interim
period, or for the year as a whole.


(2)      INVENTORIES
         -----------

         Inventories consist of the following:

                                       SEPTEMBER 30, 2004   DECEMBER 31, 2004
                                         (UNAUDITED)           (UNAUDITED)
                                         -----------           -----------

            Finished goods               $10,257,577                23,537
                                         ===========           ===========


(3)      CONVERTIBLE DEBT
         ----------------

During the nine months ended September 30, 2004, the Company issued $15,000,000
of convertible notes with interest at 5%. The notes are convertible at a rate of
80% of the average of the lowest daily volume weighted average price of the
Company's common stock for the five trading days immediately preceding the
conversion date. The Company recorded interest expense of approximately
$4,560,000 as a result of discounts amortized relating to these notes. The notes
were convertible for a period of 6 months after the effective date through
September, 2004. The payment terms have been extended through an oral agreement
with the note holder.

(4)      BASIS OF PRESENTATION
         ---------------------

These consolidated financial statements include Bio-One Corporation and all
subsidiaries. A minority interest has been reflected for any majority owned
subsidiaries. All intercompany transactions and balances have been eliminated in
consolidation.

                                       6
<PAGE>

ITEM 2.  MANAGEMENT'S PLAN OF OPERATION AND DISCUSSION AND ANALYSIS


INTRODUCTORY STATEMENTS

         Forward-Looking Statements and Associated Risks. This filing contains
forward-looking statements, including statements regarding, among other things,
(a) our Company's projected sales and profitability, (b) our Company's business
plan and growth strategies, (c) our Company's future financing plans and (d) our
Company's anticipated needs for working capital. In addition, when used in this
filing, the words "believes," "anticipates," "intends," "in anticipation of,"
"expects," and similar words are intended to identify forward-looking
statements. These forward-looking statements are based largely on our Company's
expectations and are subject to a number of risks and uncertainties, many of
which are beyond our Company's control. Actual results could differ materially
from these forward-looking statements as a result of changes in trends in the
economy and any industry in which the Company enters, competition, the
availability of financing and other factors. In light of these risks and
uncertainties, there can be no assurance that the forward-looking statements
contained in this filing will in fact occur.

OUR BUSINESS

         Bio-One is a holding company operating through subsidiaries acquired
mostly this last year. Our success will be dependent on our ability to acquire
companies in the nutritional supplement field and to effectively integrate their
operations. Until our acquisition of the assets of Physicians Nutraceutical
Laboratories, Inc. in September 2003, we had no operations, products, customers,
suppliers, or marketing and sales distribution system. Since that time, we have
acquired (i) 80% of the issued and outstanding capital stock of American
Nutritional Exchange, (ii) all of the issued and outstanding capital stock of
Interactive Nutrition Inc., (iii) 51% interest in a Chinese joint venture with
Weifang Shengtai Pharmaceuticals, (iv) 80% of the issued and outstanding capital
stock of Nutrition Sciences Corporation, (v) all of the issued and outstanding
capital stock of Healthy Choices Concepts, and (vi) 51% of the issued and
outstanding capital stock of ANI Distribution, Inc. We now have a total of
approximately six hundred (600) employees through our subsidiary companies. We
believe our acquisitions are based on a synergistic relationship between our
portfolio companies. Our strategy will be dependent upon our successfully
integrating the acquired businesses and to continue acquiring manufacturing,
marketing and distribution companies currently engaged in various aspects of
this industry.

THE NUTRITIONAL SUPPLEMENT INDUSTRY

         As the "baby boomer" population ages and life expectancies and
discretionary income increases, we believe that more emphasis is being placed on
the quality of a person's health and wellness. People want to live well as they
live longer. We believe that this will have a disproportionate effect on health
care expenditure and even more so on nutritional supplement sales, because of
the popularity of those products with older people. It is estimated that the
population of those 65 years and older will double to nearly 25% of the U.S.
population by the year 2030.

         A related trend is the growth in use of complementary and alternative
medicine services. A powerful recent trend has been the establishment of
so-called Integrative Medicine practices, in which practitioners use both
traditional and alternative methods. A central feature of complementary and
alternative medicine and integrative medicine is a search for alternatives to
drug therapy and in many cases this leads practitioners to recommending and in
some cases selling nutritional supplements. We believe this trend, which is
driven by consumer demand will further reinforce the growth in sales of consumer
health products such as nutritional supplements.

         Not all product categories within nutritional supplements are of equal
interest. While vitamin sales should not be overlooked, we believe that the real
growth in the future is likely to be in products developed to address a
particular health condition or to enhance general well-being. Bio-One intends to
focus upon specialty supplements, which require scientific research and product
development, but also command the industry's most attractive margins. Vitamins
and other nutritional supplements are sold through multiple channels of
distribution including: health food stores, drug stores, supermarkets, discount
stores, direct mail, infomercials, and direct sales organizations.

         The domestic nutritional supplement industry is highly fragmented with
a large number of small competitors involved in manufacturing and marketing
vitamins and other nutritional supplement products to health food retailers and
distributors. Many of these companies are relatively small businesses operating
on a local or regional basis. With the acquisitions of the assets of Physicians
Nutraceutical Laboratories, Inc., 80% of the capital stock of American
Nutritional Exchange, Inc. all of the issued and outstanding capital stock of
Interactive Nutrition, Inc. and the joint venture with Weifang Shengtai


                                       7
<PAGE>

Pharmaceuticals, we believe that we have the foundation to move forward with our
business strategy. Our strategy is to increase sales and profits by acquiring
companies, which we anticipate will allow us on a combined basis to become a
recognized name in the growing vitamin and nutritional supplement field. We
intend to meet these objectives by targeting additional companies which
management believes are undervalued. We will rely on our consultant, Health
Business Partners, as well as Armand Dauplaise, our President and Chief
Executive Officer, and our directors for assistance in identifying prospective
acquisition candidates and to conduct any required due diligence. We believe
that companies that are typically family owned and are looking for an exit
strategy or those family owned businesses where there are no family successors
or the successors do not want to operate the business are prime acquisition
candidates. In some cases we believe that we can offer portfolio companies,
management expertise and a range of technology solutions that might not
otherwise be available to them.

         On June 20, 2003, we entered into an agreement with Health Business
Partners, pursuant to which Health Business Partners agreed to assist Bio-One in
identifying acquisition candidates. Heath Business Partners is a merger and
acquisition advisory firm specializing in the nutrition and customer healthcare
industries. As an advisor, principal or general partner, Health Business
Partners has been involved in more than 35 transactions in the nutrition and/or
customer healthcare industries. Pursuant to the agreement, Bio-One is obligated
to pay Health Business Partners $2,000 per day with a $6,000 cap per month and a
success fee based upon the size of future acquisitions. Health Business Partners
earned a success fee for the search and identification of the acquisitions of
80% of the issued and outstanding capital stock of American Nutritional
Exchange, Inc. and all of the issued and outstanding capital stock of
Interactive Nutrition Inc.

         Businesses acquired or formed by us are intended to have a synergistic
relationship to one another. We acquired a manufacturer of nutritional
supplements and powders to internalize, as much as possible, the manufacturing
needs of our portfolio companies. We acquired a distributor of nutritional
supplement products and expanded the distribution area through acquisition in
order to distribute products manufactured and developed by our portfolio
companies. We formed direct mail, infomercial and direct to consumer companies
to service our portfolio companies. In all cases we anticipate that our
portfolio companies will provide services to independent customers and clients
and are, or will become self-sustaining.

         We intend to acquire businesses that are, for the most part,
self-sustaining and can finance growth from internal resources or locally
financed debt. Except where there are significant increases in business
generated through inter-company transactions, we do not expect to make further
contributions of capital to our portfolio companies.

         We have formed a core management group that provides support to our
portfolio companies in the areas of operations, marketing, business development,
financial services and technology solutions. In addition, each portfolio company
can call on the expertise of peers for advice, collaboration and project cost
sharing. Representatives from each portfolio company meet each quarter for a
review of results, needs, advice, support and collaboration. However, market
conditions, the trading price and volume of our common stock as well as the
uncertainty of the nature of any acquisition may limit our ability to finance
future operations.

THE NUTRITIONAL SUPPLEMENT MARKET

         With an aging baby boom population striving to retain their health and
vitality, nutritional supplements and vitamins are in growing demand.

         Nutritional supplements are natural, nutritional, biologically active
materials formulated to provide specific health benefits to humans. Nutritional
supplements are biologically active materials, derived from plant, microbial or
animal sources, which are formulated to provide specific health and productivity
benefits including, but not limited to, functional foods, fermented foods,
phytochemicals, microbial feed additives, probiotics, herbal products, vitamins
and health supplements.

         Bio-One's focus is to market products in the nutritional supplement
industry that are manufactured by its wholly owned subsidiary. We intend to
vertically integrate production, marketing, and distribution.

PNLABS, INC.

         On September 11, 2003, our wholly-owned subsidiary, PNLabs, Inc.,
consummated the acquisition of the assets of Physicians Nutraceutical
Laboratories, Inc. The purchased assets, valued at $108,000, included inventory,
accounts receivable, office furniture, the rights to 5 products and all rights
to the operating business. The consideration given for the purchase of the
assets of Physicians Nutraceutical Laboratories was a five-year, 5% royalty on
all monthly net sales of PNLabs and committed us to immediately provide $50,000


                                       8
<PAGE>

for working capital. Further, pursuant to our agreement with Physicians
Nutraceutical Laboratories, up to an additional $1.4 million of development
capital may be committed depending on future operating results. The $1.4 million
of development capital was at the rate of $50,000 per month from September
through December 2003. It is now at the rate of $50,000 per month through
December 2004, subject to the business operating according to its projections
for revenues and profits. The development capital is being allocated to develop
products distribution channels for direct mail, infomercials, e-commerce,
retail, radio, and a physician's network. There is no negative financial or
legal implication to Bio-One if we do not meet the $1.4 million capital
referenced above. PNLabs markets five products. We intend to continue to market
these five products as well as add new products, and further develop a
comprehensive marketing plan for all of our products.

MANUFACTURING

         We have acquired a manufacturing facility pursuant to our acquisition
of Interactive Nutrition, which should allow us to produce our vitamins and
supplements, as well as manufacture products and increase our revenues by
offering services to third party distributors who market nutritional
supplements. Interactive Nutrition is a manufacturer and distributor of branded,
specialty nutritional supplements, which are currently marketed in the United
States, Canada and Hong Kong. Interactive Nutrition specializes in providing
research, development and custom formulation of premium nutritional supplement
private-label formulas, including over-the-counter, pharmaceutical grade,
private-label formulations. Interactive Nutrition's products include: SoyOne(TM)
Protein for Women, SoyOne(TM) Nutrition Bars, ISOWhey(TM) Protein Powder,
Creative Blast(TM) and Total Whey. Interactive Nutrition is a Current Good
Manufacturing Practices manufacturer. Interactive Nutrition operates in a 40,000
square-foot facility in Ottawa, Canada. The 75-employee business continues to be
operated with its original management team. Interactive Nutrition operates under
strict standards enacted by the Government of Canada for manufacturers of
nutritional supplements.

         Now that we have acquired the manufacturing facility, we intend to
focus on the distributors who market nutritional supplements.

         Our management believes that the principal markets in which we compete
are competitive and fragmented, with competitors in both the private label
market and health supplements market. The term "private label market" describes
distributors' products that are manufactured by others. We do not believe that
this is the most efficient way to operate.

SOURCES AND AVAILABILITY OF RAW MATERIALS AND PRINCIPAL SUPPLIERS

         We obtain the raw materials for the manufacture of our products from
other sources. We believe that there are currently in excess of two hundred
(200) primary suppliers of raw materials within the U.S. We do not anticipate
having contracts with any entities or persons committing such suppliers to
provide the materials required for the production of our products. Raw materials
including all natural herbs and minerals are plentiful worldwide.

MARKETING

         We now have marketing, sales and distribution systems in place within
each of our subsidiaries. The following discussion is predicated upon us
generating significant revenues and raising additional capital to fully
implement our vertical integration strategy. Through each of our subsidiaries,
we now have a sales and marketing/customer service department dedicated to
selling our services, products and technologies in the nutritional supplement
industry.

         The primary markets for our products and services are in the preventive
and alternative healthcare fields. Preventive and alternative healthcare
programs and systems establish very specific requirements in helping improve and
maintain an individual's health. We believe that the market is global and
growing rapidly. As nutritional supplements use combined with preventive and
alternative healthcare become more readily accepted, we believe physicians and
other healthcare providers will be targeted for marketing purposes.

DEPENDENCE ON NEW PRODUCTS

         Our ability to grow will be somewhat dependent upon the success of our
acquisitions integration program and our ability to introduce new and innovative
products into such markets. We will attempt to introduce additional products in
our existing markets from time to time. The success of new products is subject
to a number of conditions, including developing products that will appeal to
customers and comply with existing regulations at the time of introduction.

                                       9
<PAGE>

COMPETITION

         Management of Bio-One believes that competition in our principal
markets and the private label market is intense and fragmented. We are in the
process of continually developing our marketing strategies and product lines and
expect that both will involve an ever-changing and evolving process. We will
continually attempt to competitively price our products, provide superior
quality products, and achieve success through attentive and efficient customer
service and effective marketability strategies. We believe that there are many
well-established competitors with greater financial resources, as well as new
market entrants in the nutritional supplement industry.

         NBTY is the industry leader with $1.2 billion in annual sales. Less
than twenty (20) companies are realizing annual revenues in excess of $100
million, including: Leiner Health Products, American Home Products, Pharmavite
and Nutraceutical according to the Nutrition Business Journal.

TRADEMARKS

PROPRIETARY PROTECTION

         Our business prospects depend upon our ability to capitalize on
favorable consumer recognition of our trade names. Except for the trademarks
held by our recent acquisitions, we do not currently hold any other trademarks.
However, as we continue to pursue our vertical integration strategy, we intend
to rely on trademarks obtained from our acquired companies. In addition, we
anticipate that we will also rely on trade secrets and proprietary know-how, and
employ various methods to protect our concepts. Unlike pharmaceutical products
that rely on specific combinations of drugs and chemicals, patents cannot
protect. However, management believes that simply knowing the ingredients of a
nutritional supplement product does not mean that other manufacturers can
duplicate the product.

GOVERNMENTAL REGULATION

         The manufacturing, processing, formulating, packaging, labeling,
distributing, selling and advertising of our products are subject to regulation
by one or more federal agencies. The most active regulation has been
administered by the Food and Drug Administration ("FDA") which regulates our
products pursuant to the Federal Food, Drug and Cosmetic Act ("FDCA") and
regulations promulgated thereunder. In particular, the FDA regulates the safety,
manufacturing, labeling and distribution of dietary supplements, including
vitamins, minerals and herbs, food additives, food supplements, over-the-counter
drugs and prescription drugs, medical devices and cosmetics. In addition, the
FTC has overlapping jurisdiction with the FDA to regulate the labeling,
promotion and advertising of dietary supplements, over the counter drugs,
cosmetics and foods.

         Although the dietary supplement industry is not subject to regulation
by the FDA and local authorities, dietary supplements, including vitamins,
minerals, herbs and other dietary ingredients, now have been statutorily
affirmed as a "food." Dietary supplement companies are authorized to make
substantiated statements of nutritional support and, subject to several possible
limitations, to manufacture and market substantiated safe dietary supplement
products without FDA pre-clearance. Failure to comply with applicable FDA
requirements can result in sanctions being imposed on Bio-One or the
manufacturers of any of our other products, including but not limited to fines,
injunctions, product recalls, seizures and criminal prosecution.

         Compliance with applicable FDA and any state or local statutes is
crucial. Although we believe that we are in compliance with applicable statutes,
should the FDA amend its guidelines or impose more stringent interpretations of
current laws or regulations, we may not be able to comply with these new
guidelines. We are unable to predict the nature of such future laws,
regulations, interpretations or applications, nor can we predict what effect
additional governmental regulations or administrative orders, when and if
promulgated, would have on our business in the future. These regulations could,
however, require the reformation of certain products to meet new standards,
market withdrawal or discontinuation of certain products not able to be
reformulated, imposition of additional record keeping requirements, expanded
documentation regarding the properties of certain products, expanded or
different labeling and/or additional scientific substantiation.

         The FDCA has been amended several times with respect to dietary
supplements, most recently by the Dietary Supplement Health and Education Act of
1994 ("DSHEA"). DSHEA was enacted on October 15, 1994. It provides a
statutory framework governing the composition and labeling of dietary
supplements. DSHEA provides a regulatory framework to ensure safe, quality
dietary supplements and the dissemination of accurate information about such
products. Under DSHEA, dietary supplements are generally excluded from the legal
definition of "food additive." With respect to composition, DSHEA created a new
class of "dietary supplements", consisting of vitamins, minerals, herbs, amino


                                       10
<PAGE>

acids and other dietary substances for human use to supplement the diet, as well
as concentrates, metabolites, extracts or combinations of such dietary
ingredients. Generally, under DSHEA, dietary ingredients that were on the market
before October 15, 1994 may be sold without FDA pre-approval and without
notifying the FDA. On the other hand, a new dietary ingredient (one not lawfully
on the market before October 15, 1994) requires proof that it has been present
in the food supply as an article used for food without being chemically altered,
or evidence of a history of use or other evidence of safety establishing that it
is reasonably expected to be safe. The FDA must be supplied with such evidence
at least seventy-five (75) days before the initial introduction into interstate
commerce use of a new dietary ingredient. The FDA may not accept the evidence of
safety for any new dietary ingredients that we may decide to use, and the FDA's
refusal to accept such evidence could result in regulation of such dietary
ingredients as adulterated until such time as reasonable expectation of safety
for the ingredient can be established to the satisfaction of the FDA.

         As for labeling, DSHEA permits "statements of nutritional support" for
dietary supplements without FDA pre approval. Such statements may describe how
particular dietary ingredients affect the structure, function or general well
being of the body, or the mechanism of action by which a dietary ingredient may
affect body structure, function or well being (but may not state that a dietary
supplement will diagnose, mitigate, treat, cure or prevent a disease). A company
making a statement of nutritional support must possess substantiating evidence
for the statement, and, for such statements that are not about the effects on
the body as a result of a dietary supplement used as a tool for its nutritive
value and are not otherwise "health claims," disclose on the label that the FDA
has not reviewed that statement and that the product is not intended for use for
a disease, and notify the FDA of the statement within thirty (30) days after its
initial use. The manner for making the disclosure and notifying the FDA are set
forth in the regulations. However, the FDA may determine that a given statement
of nutritional support that we decide to make is a drug claim rather than an
acceptable nutritional support statement. Such a determination would require
deletion of the drug claim or our submission, and the FDA's approval of a New
Drug Application ("NDA"), which would entail costly and time-consuming clinical
studies. In addition, DSHEA allows the dissemination of "third party
literature", publications such as reprints of scientific articles linking
particular dietary ingredients with health benefits. Third party literature is
exempted from FDA regulation as dietary supplement "labeling" and may be used in
connection with the sale of dietary supplements to consumers. Such a publication
may be so used if, among other things, it is not false or misleading, no
particular manufacturer or brand of dietary supplement is promoted and a
balanced view of available scientific information on the subject matter is
presented. There can be no assurance, however, that all pieces of third party
literature that may be disseminated in connection with our products will be
determined by the FDA to satisfy each of these requirements, and any such
failure could subject the product involved to regulation as a new drug or as a
"misbranded" product.

         DSHEA permits substantiated, truthful and non misleading statements of
nutritional support to be made in labeling, such as statements describing
general well being resulting from consumption of a dietary ingredient or the
role of a nutrient or dietary ingredient in affecting or maintaining structure
or function of the body. Any statement of nutritional support beyond traditional
claims must be accompanied by disclosure that the FDA has not evaluated such
statement and that the product is not intended to cure or prevent any disease.
We anticipate that the FDA will promulgate Good Manufacturing Practices
("GMPs"), which are specific to dietary supplements and require at least some of
the quality control provisions contained in the GMPs for drugs. Management
anticipates that the FDA may promulgate GMP regulations authorized by DSHEA,
which are specific to dietary supplements. GMP regulation would require
supplements to be prepared, packaged and held in compliance with such rules, and
may require similar quality control provisions contained in the GMP regulations
for drugs. If the FDA adopts GMP regulations specific to dietary supplements, we
may not be able to comply with such GMP rules upon promulgation or without
incurring material expenses to do so.

         Our products and product related activities may also be subject to
regulation by other regulatory agencies, including but not limited to the
Federal Trade Commission ("FTC"), the Consumer Products Safety Commission, the
United States Department of Agriculture, the United States Postal Service, the
United States Environmental Protection Agency and the Occupational Safety and
Health Administration. These activities are also regulated by various agencies
of the states and localities in which our products are sold. The products and
product-related activities of Interactive Nutrition Inc. and our Chinese joint
venture are regulated by the applicable regulatory agencies in Canada and China.

         Advertising of dietary supplement products is subject to regulation by
the FTC under the Federal Trade Commission Act ("FTCA"). Section 5 of the FTCA
prohibits unfair methods of competition and unfair or deceptive trade acts or
practices in or affecting commerce. Section 12 of the FTCA provides that the
dissemination or the causing to be disseminated of any false advertising
pertaining to drugs or foods, which would include dietary supplements, is an
unfair or deceptive act or practice. Under the FTC's Substantiation Doctrine, an
advertiser is required to have a "reasonable basis" for all objective product
claims before the claims are made. Pursuant to this FTC requirement, we are
required to have adequate substantiation of all material advertising claims made
for its products. Failure to adequately substantiate claims may be considered
either deceptive or unfair practices.

                                       11
<PAGE>

         In recent years the FTC has initiated numerous investigations of
dietary supplement and weight loss products and companies. The FTC has recently
issued a guidance document to assist supplement marketers of dietary supplement
products in understanding and complying with the substantiation requirement.

         The FTC is authorized to use a variety of processes and remedies for
enforcement, both administratively and judicially including compulsory process,
cease and desist orders, and injunctions. FTC enforcement can result in orders
requiring, among other things, limits on advertising, corrective advertising,
consumer redress, divestiture of assets, rescission of contracts and such other
relief as may be deemed necessary. State and local authorities can also regulate
advertising and labeling for dietary supplements and conventional foods.

         We believe that any product or supplement we distribute will be either
G.R.A.S. (Generally Regarded As Safe) listed by the FDA or do not currently
require extended regulatory approval. Recent legislation has resulted in a
regulatory environment, which sets what we believe to be reasonable limitations
and guidelines on health claims and labeling for natural products. We believe
that current and reasonably foreseeable governmental regulation will have
minimal impact on our business. The FTC oversees claims made by us and other
companies in the nutritional supplement industry. The FTC under the Federal
Trade Commission Act prohibits the use of unfair or deceptive trade practices,
including false or misleading advertising. The FTC in recent years has brought a
number of actions challenging claims by companies. These actions stem from the
Retail Truth In Labeling laws. In the future, we may be subject to additional
laws or regulations administered by the FDA or other federal, state or foreign
regulatory authorities, the repeal of laws or regulations, which Bio-One
considers favorable, or more stringent interpretations of current laws or
regulations. In fact, the FDA strictly regulates dietary supplements, as opposed
to nutritional supplements, which are subject only to Truth In Labeling laws.
Should we begin producing nutritional supplements in the United States, or
should one of our products be determined by the FDA to be a dietary supplement,
more stringent regulation of our products may take place. Compliance with these
additional rules and regulations may result in a considerable expense or may
cause us to have to discontinue production of some or all of our then current
products. New laws and regulations could, however, require the reformulation of
certain products to meet new standards, the recall or discontinuance of certain
products not able to be reformulated, imposition of additional record keeping
requirements, or expanded documentation of the properties of certain products,
expanded or different labeling and scientific substantiation.

COMPLIANCE WITH ENVIRONMENTAL LAWS

         We believe that we are in compliance with all relevant environmental
laws. In fact, we believe there are no environmental laws, which directly impact
our business. Due to the nature of our operations, we believe that the cost of
complying with environmental laws will not have a significant effect on our
operations.

RESEARCH & DEVELOPMENT

         In order to stay competitive, we must periodically introduce new
products. This involves research and development. To the extent that we have
sufficient capital, we intend to actively pursue the research, development,
manufacture and distribution of nutritional supplements.

OUR ACQUISITION STRATEGY

         We intend to continue developing as a vertically integrated company in
the nutritional supplement industry. In furtherance thereof, we believe the
acquisition of the assets of Physicians Nutraceutical Laboratories, 80% of the
capital stock of American Nutritional Exchange, Inc., the stock of Interactive
Nutrition Inc., our 51% interest in our Chinese joint venture and ANI
Distribution's (our 51% owned subsidiary) acquisition of the assets of Florida
Sport Nutrition Distributors, Inc. represents the first steps in our strategy.
We intend to continually seek to acquire additional manufacturing, distribution
and marketing companies that we believe have the ability to profitably operate
their business and whose revenues can be increased by means of improved
operating efficiencies in a vertically integrated company. We may seek to
acquire companies with lower earnings, if management believes that the products,
facilities, management or mix will fit within our overall objective to become a
leader in the nutritional supplement industry. We intend to seek opportunities
which we believe have the potential of long-term growth as opposed to short-term
earnings.


                                       12
<PAGE>


NO OPPORTUNITY FOR SHAREHOLDER EVALUATION OR APPROVAL OF BUSINESS COMBINATIONS

         Due to nondisclosure and confidentiality agreements which we may be
required to execute, our shareholders will, in all likelihood, not receive nor
otherwise have the opportunity to evaluate any financial or other information
which will be made available to us in connection with selecting a potential
business combination until after we have entered into an agreement to effectuate
a business combination. As a result, shareholders will be almost entirely
dependent on the judgment and experience of management in connection with our
acquisition strategy.

ACQUISITION CRITERIA

         Health Business Partners assists Bio-One management in identifying
acquisition candidates. Health Business Partners is a merger and acquisition
advisory firm specializing in the nutrition and customer healthcare industries.
As an advisor, principal or general partner, Health Business Partners has been
involved in more than 35 transactions in the nutrition and/or customer
healthcare industries. Management intends to consider, among other factors, the
following in targeting a business, which are not listed in any particular order:

         o        financial condition and results of operation of the target
                  business;

         o        the distribution channel of the target business;

         o        the location of the target business;

         o        growth potential and projected financial performance of the
                  target business;

         o        experience and skill of management and availability of
                  additional personnel of the target business;

         o        capital requirements of the target business;

         o        competitive position of the target business;

         o        stage of development of the product, process or service of the
                  target business;

         o        degree of current or potential market acceptance of the
                  product, process or service of the target business;

         o        possible proprietary features and possible other protection of
                  the product, process or service of the target business; and

         o        costs associated with effecting the business combination.

         The foregoing criteria are not intended to be exhaustive; any
evaluation relating to the merits of a particular acquisition will be based, to
the extent relevant, on the above factors as well as other considerations deemed
relevant by us in connection with any acquisition we conclude. In many
instances, it is anticipated that the historical operations of a target business
may not necessarily be indicative of the potential for the future because of the
possible need to shift marketing approaches substantially, expand significantly,
change product emphasis, change or substantially augment management, or make
other changes.

         In connection with our evaluation of a prospective target business,
management anticipates that it will conduct a due diligence review which will
encompass, among other things, meetings with incumbent management and inspection
of facilities, as well as review of financial or other information which will be
made available to us. The time and costs required to select and evaluate a
target business (including conducting a due diligence review) and to structure
and consummate the business combination (including negotiating relevant
agreements and preparing requisite documents for filing pursuant to applicable
securities laws and state "blue sky" and corporation laws) cannot presently be
ascertained with any degree of certainty.

         If our securities are issued as part of an acquisition, such securities
are required to be issued either in reliance upon exemptions from registration
under applicable federal or state securities laws or registered for public
distribution. We intend to target those companies where an exemption from
registration would be available; however, no assurances can be made that we will
be able to rely on such exemptions. Registration of securities typically
requires significant costs and time delays are typically encountered. In
addition, the issuance of additional securities and their potential sale could
depress the price of our common stock. Further, such issuance of additional
securities would result in a decrease in the percentage ownership of present
shareholders.

                                       13
<PAGE>


CODE OF ETHICS

         Bio-One has adopted a formal code of ethics that applies to our
principal executive officer, principal accounting officer, all other officers,
directors and employees. This code of ethics is filed with the Securities and
Exchange Commission as an exhibit to our 10KSB for the fiscal year ended
December 31, 2003.

RECENT DEVELOPMENTS

         On August 3, 2004 Bio-One appointed Bob Ramsey as vice president of
operations. He is a veteran in operations and merchandising who will be
responsible for expanding sales and marketing in Bio-One's North American
operations including PN Labs, American Nutritional, ANI Distribution,
Interactive Nutrition International, Nutrition Sciences Corporation and Healthy
Choices Concepts. Mr. Ramsey has extensive background in strategic
merchandising, marketing and operations which will help us achieve the goals of
building our business and generating shareholder value. He has served as
executive vice president for retail and eCommerce development at S. Freedman &
Sons; has held senior operational and marketing positions with a number of
companies including Beverage Club, Inc., Cosmetic Center, Inc., Dart Group and
Drug Emporium. His experience includes expansion of new stores in mass-market
large box retail, marketing and advertising at a national and regional level,
and the development and launch of Internet marketing programs.

         On July 20, 2004, Bio-One entered into a letter of intent to acquire a
51% interest in a Chinese herbal medicine company in Henan Province. The company
is an integrated business that includes Chinese herbal medicine, nutrition
products, drugs and medical devices. Their distribution channels are to
agencies, wholesalers, retailers, hospitals, and direct to consumers.
Consummation of this transaction is contingent on certain conditions, including,
but not limited to, obtaining certified audits in accordance with U.S. G.A.A.P.,
legal due diligence, obtaining approval from the Peoples Republic of China and
completing the required documentation to close the transacion.

         On June 21, 2004, Bio-One's 51%-owned subsidiary, ANI Distribution,
Inc. acquired the assets of Florida Sport Nutrition Distributors, Inc. The terms
of the acquisition included a cash payment of $175,000 and a promissory note in
the amount of $175,000. The promissory note provides for the payment of the
balance of the purchase price in eight consecutive quarterly installments of
$32,875 with the first payment to be made 3 months following the date of
closing. No interest is payable on the notes when not in default. Florida Sport
Nutrition Distributors is a Tampa, Florida-based wholesale distributor of
nationally branded nutritional supplements. The company's distribution channels
include retailers representing independents, large and small chain vitamin
outlets, health clubs and convenience stores. As part of the transaction,
Bio-One assumed $216,000 of liabilities from Florida Sport Nutrition
Distributors.

         On June 10, 2004, we formed Healthy Choices Concepts, in which we own
100% of the issued and outstanding shares of capital stock. Healthy Choices
Concepts was formed to provide infomercial and direct to consumer solutions to
our portfolio companies, sell its own products and be a vendor of infomercial
marketing programs and direct to consumer solutions to independent clients. We
have undertaken to fund Healthy Choices Concepts to a maximum amount of
$250,000. To date, we have funded Healthy Choices Concepts to the extent of
$97,000. Healthy Choices Concepts is in the formation stage.

         On June 1, 2004, Bio-One entered into a letter of intent to acquire a
51% interest in a Chinese herbal medicine company in Guangzhou Province. The
company is an integrated business that includes research and development,
manufacturing, sales and marketing. Consummation of this transaction is
contingent on certain conditions, including, but not limited to, obtaining
certified audits in accordance with U.S. G.A.A.P., legal due diligence,
obtaining approval from the Peoples Republic of China and completing the
required cocumentation to close the transacion.

         On April 15, 2004, we formed ANI Distribution, Inc. in which we own 51%
of the issued and outstanding shares and the principals of American Nutritional
Exchange, Inc. own 49% of the issued and outstanding shares. ANI Distribution
was formed to acquire distributors of nutritional supplements and related
products in areas outside of the distribution area of American Nutritional
Exchange. We will fund ANI Distribution only to the extent that it acquires
distribution companies. Acquisitions are expected to be self sustaining. ANI
Distribution is managed by the principals of American Nutritional Exchange as
part of its overhead structure.

         In April 2004, we formed Nutrition Sciences Corporation, in which we
own 80% of the issued and outstanding shares of capital stock and the senior
manager of that company owns 20% of the issued and outstanding shares of capital
stock. Nutrition Sciences was formed to provide direct mail solutions to our
portfolio companies, sell its own products and be a vendor of direct mail
solutions to independent clients. We have undertaken to fund Nutrition Sciences
to a maximum amount of $550,000. To date, we have funded Nutrition Sciences to
the extent of $303,000. Nutrition Sciences generates its revenues from sales of
its own products and by projects from portfolio companies. Currently Nutrition
Sciences has developed two products, Activene to address fatigue and enhance
energy; and Prostia, to address men's prostate health; and has additional
products under development.

                                       14
<PAGE>

         On April 4, 2004, we consummated a joint venture transaction with
Weifang Shengtai Pharmaceuticals Co. Ltd., a company organized under the laws of
the People's Republic of China and located in Changle County, Shandong Province.
Pursuant to the Joint Venture Agreement, we acquired 51% of the joint venture
entity with Weifang Shengtai Pharmaceuticals for a cash payment equal to
$2,000,000 and 2,090,000 shares of our Series A Preferred Stock priced at $2.00
per share. Weifang Shengtai Pharmaceuticals is a manufacturer and distributor of
glucose in China. Their product distribution is conducted through direct sales
from their sales department and sales branches with offices in nine major cities
and is a supplier of glucose to many of China's major pharmaceutical companies.
In January, Shengtai moved into their newly constructed 35-acre facility. The
450-employee business continues to be operated with its original management
team.

         On March 31, 2004, we consummated the acquisition of all the issued and
outstanding capital stock of Interactive Nutrition Inc., a company organized
under the laws of Canada. Pursuant to a Share Purchase Agreement, we acquired
all of the issued and outstanding capital stock of Interactive Nutrition for an
aggregate purchase price of C$30,000,000. We issued a Convertible Promissory
Note in the principal amount of C$15,000,000, which we are obligated to pay 57
consecutive monthly installments of C$263,158 commencing on July 1, 2004.
Interactive Nutrition is a manufacturer and distributor of branded, specialty
nutritional supplements, which are currently marketed in the United States,
Canada and Hong Kong. Interactive Nutrition specializes in providing research,
development and custom formulation of premium nutritional supplement
private-label formulas, including over-the-counter, pharmaceutical grade,
private-label formulations. Interactive Nutrition's products include: SoyOne(TM)
Protein for Women, SoyOne(TM) Nutrition Bars, ISOWhey(TM) Protein Powder,
Creative Blast(TM) and Total Whey. Interactive Nutrition is a Current Good
Manufacturing Practices manufacturer. Interactive Nutrition operates in a 40,000
square-foot facility in Ottawa, Canada. The 75-employee business continues to be
operated with its original management team.

         As of March 31, 2004, we issued a Secured Convertible Debenture in the
principal amount of $15 million. The convertible debenture is convertible into
shares of our common stock at a price per share that is equal to the lesser of
(i) an amount equal to $0.75 or (ii) an amount equal to 80% of the average of
the lowest daily volume weighted average price of our common stock for the five
trading days immediately preceding the conversion date. The convertible
debenture accrues interest at a rate of 5% per year and is convertible at the
holder's option. The convertible debenture has a term of 7 months and is secured
by the assets of Bio-One and a second position security interest in the assets
of Interactive Nutrition Inc. At Bio-One's option, the convertible debenture may
be paid in cash or converted into shares of our common stock unless converted
earlier by the holder. The original payment terms were $1,000,000 per week for
five weeks commencing after May 1, 2004, resuming after July 1, 2004 and after
September 1, 2004. These payment terms have been extended through an oral
agreement with Cornell Capital Partners. Except after an event of default, as
set forth in the Secured Convertible Debenture be entitled to convert such
debenture for a number of shares of common stock of Bio-One in excess of that
number of shares which, upon giving effect to such conversion, would cause the
aggregate number of shares of common stock beneficially held by such holder and
its affiliated to exceed 4.99% of the outstanding shares of common stock of
Bio-One. As of November 1, 2004 $4.2 million had been repaid through proceeds
under the Standby Equity Distribution Agreement.

         On March 26, 2004, we entered into a Standby Equity Distribution
Agreement with Cornell Capital Partners. Pursuant to the Standby Equity
Distribution Agreement, we may, at our discretion, periodically issue and sell
shares of our common stock for a total purchase price of $50 million. If we
request advances under the Standby Equity Distribution Agreement, Cornell
Capital Partners will purchase shares of common stock of Bio-One for 100% of the
lowest closing bid price on the Over-the-Counter Bulletin Board or other
principal market on which our common stock is traded for the 5 days immediately
following the advance notice date. Cornell Capital Partners will retain 5% of
each advance under the Standby Equity Distribution Agreement. We may not request
advances in excess of a total of $50 million. The maximum of each advance is
equal to $525,000 and up to a maximum of $2,100,000 in any thirty-day period.

         On February 5, 2004, Bio-One executed a Secured Promissory Note payable
to Cornell Capital Partners, LP in the principal amount of $5,000,000. The
Promissory Note accrued interest at an annual rate of 12% and was payable out of
Bio-One's cash or out of the net proceeds received by Bio-One under our Equity
Line of Credit Agreement, dated July 25, 2002 with Cornell Capital Partners. The
Promissory Note was secured by all of the assets of Bio-One. As of June 30,
2004, this Promissory Note had been repaid in full.

         On February 4, 2004, Bio-One consummated a stock acquisition with
American Nutritional Exchange, Inc., a Florida corporation. Pursuant to the
Stock Purchase Agreement, Bio-One purchased shares of American Nutritional
capital stock representing 80% of the votes of all issued and outstanding shares
of American Nutritional capital stock for: (1) a purchase price in an amount
equal to $1,000,000 payable in installments and (2) a credit line to be made
available to American Nutritional in the principal amount of $1,000,000, which
may be drawn down by American Nutritional in traunches during 2004. Pursuant to
the Stock Purchase Agreement, Bio-One is entitled to receive 30% of any future
distribution of profits of American Nutritional and/or 30% of any future
distribution of proceeds from a sale of American Nutritional. American
Nutritional is a Florida-based business that is a wholesale distributor of
nationally branded nutritional supplements. American Nutritional sells


                                       15
<PAGE>

nutritional supplement products to retail stores representing independents,
large and small chain vitamin outlets, health clubs and convenience stores
throughout the Southeast United States. American Nutritional has achieved
distribution rights with approximately 25 of the manufacturers of nutritional
brands in the natural products industry. The 35-employee business continues to
be operated with its original management team.

EMPLOYEES

         We currently have approximately six hundred (600) employees employed
within our subsidiaries and China joint venture. We are currently reviewing our
personnel needs for the remainder of 2004 and beyond. As of the date hereof, we
anticipate hiring additional employees, which would include management,
marketing and support staff.

CRITICAL ACCOUNTING POLICIES

         The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires
management to make a wide variety of estimates and assumptions that affect (i)
the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities as of the date of the financial statements, and (ii) the
reported amounts of revenues and expenses during the reporting periods covered
by the financial statements. Our management routinely makes judgments and
estimates about the effect of matters that are inherently uncertain. As the
number of variables and assumptions affecting the future resolution of the
uncertainties increases, these judgments become even more subjective and
complex. We have identified certain accounting policies that are most important
to the portrayal of our current financial condition and results of operations.
Our significant accounting policies are disclosed in Note 1 of the Notes to the
audited Financial Statements included in our Form 10-KSB for the fiscal year
ended December 31, 2003.

RECENT ACCOUNTING PRONOUNCEMENTS

         New accounting pronouncements that have a current or future potential
impact on our financial statements are as follows:

         In April 2003, the FASB issued SFAS No. 149, "Amendment of Statement
133 on Derivative Instruments and Hedging Activities." The Statement amends and
clarifies accounting and reporting for derivative instruments, including certain
derivative instruments embedded in other contracts and for hedging activities
under SFAS No. 133, "Accounting for Derivative Instruments and Hedging
Activities." This Statement is effective for contracts entered into or modified
after September 30, 2003, except as stated below and for hedging relationships
designated after September 30, 2003. In addition, except as stated below, all
provisions of this Statement should be applied prospectively. The provisions of
this Statement that relate to SFAS No. 133 Implementation Issues that have been
effective for fiscal quarters that began prior to June 15, 2003, should continue
to be applied in accordance with their respective effective dates. In addition,
paragraphs 7(a) and 23(a), which relate to forward purchases or sales of
when-issued securities or other securities that do not yet exist, should be
applied to both existing contracts and new contracts entered into after
September 30, 2003. Adoption of this Statement on July 1, 2003 did not have a
significant impact on the financial position or results of operations of the
Company.

         In May 2003, the FASB issued SFAS No. 150, "Accounting for Certain
Financial Instruments with Characteristics of both Liabilities and Equity." This
Statement establishes standards for how an issuer classifies and measures
certain financial instruments with characteristics of both liabilities and
equity. It requires that an issuer classify a financial instrument that is
within its scope as a liability, or an asset in some circumstances. Many of
those instruments were previously classified as equity. This Statement is
effective for financial instruments entered into or modified after May 31, 2003,
and otherwise is effective at the beginning of the first interim period
beginning after June 15, 2003. Adoption of this Statement on July 1, 2003 did
not have a significant impact on the financial position or results of operations
of the Company.

                                       16
<PAGE>

         In May 2003, the Emerging Issues Task Force ("EITF") of the FASB
reached a consensus on Issue No. 00-21, "Accounting For Revenue Arrangements
with Multiple Deliverables", which establishes criteria for whether revenue on a
deliverable can be recognized separately from other deliverables in a multiple
deliverable arrangement. The criteria considers whether the delivered item has
stand-alone value to the customer, whether the fair value of the delivered item
can be reliably determined and the customer's right of return for the delivered
item. This Issue applies to multiple deliverable revenue arrangements initiated
in reporting periods beginning after June 15, 2003. Adoption of this Issue did
not have a significant impact on the financial position or results of operations
of the Company.

         In May 2003, the EITF reached a consensus on Issue No. 01-8,
"Determining Whether an Arrangement Contains a Lease", which requires capital
lease treatment for arrangements containing an embedded lease, thereby conveying
the right to control the use of property, plant or equipment (collectively,
"property") whether the right to control the use of the property is explicitly
or implicitly specified. The right is conveyed if the purchaser (lessee) obtains
physical or operational control of the underlying property or takes
substantially all of its output. This Issue applies prospectively to new or
modified arrangements beginning after May 28, 2003. Adoption of this Issue did
not have a significant impact on the financial position or results of operations
of the Company.

         In December 2003, the FASB issued SFAS No. 132 (revised 2003),
"Employers' Disclosures about Pensions and Other Postretirement Benefits - an
amendment of FASB Statements No. 87, 88 and 106". This Standard revises
employers' disclosures about pension plans and other postretirement benefit
plans. It does not change the measurement or recognition of those plans required
by SFAS No. 87, "Employers' Accounting for Pensions", No. 88, "Employers'
Accounting for Settlements and Curtailments of Defined Benefit Pension Plans and
for Termination Benefits", and No. 106, "Employers' Accounting for
Postretirement Benefits Other Than Pensions". The new rules require additional
disclosures about the assets, obligations, cash flows and net periodic benefit
cost of defined benefit pension plans and other postretirement benefit plans.
The required information should be provided separately for pension plans and for
other postretirement benefit plans. This Statement is effective for financial
statements with fiscal years ending after December 31, 2003, with a delayed
effective date for certain disclosures and for foreign plans. Adoption of this
Statement on December 31, 2003 did not have a significant impact on the
financial position or results of operations of the Company.

         In December, 2003, the Staff of the Securities and Exchange Commission
("SEC") issued Staff Accounting Bulletin ("SAB") No. 104. This SAB's primary
purpose is to rescind accounting guidance contained in SAB 101 related to
multiple element revenue arrangements, superseded as a result of the issuance of
EITF Issue No. 00-21. Additionally, the SAB rescinded the SEC's Revenue
Recognition in Financial Statements Frequently Asked Questions and Answers (the
"FAQ") issued with SAB 101 that had been codified in SEC Topic 13, Revenue
Recognition. Selected portions of the FAQ have been incorporated into this SAB.
While the wording of this SAB has changed to reflect the issuance of EITF Issue
No. 00-21, the revenue recognition principles of SAB 101 remain largely
unchanged. Adoption of this SAB on December 31, 2003 did not have a significant
impact on the financial position or results of operations of the Company.

SECURITIES AND EXCHANGE COMMISSION INQUIRY

         The Company has received requests from the SEC's Division of
Enforcement for certain documents and information, including documents regarding
recent and prospective acquisitions and business arrangements with certain
companies, prospective investors, recent issuances of Company securities, and
financial statements with respect to recent acquisitions. The Company is
responding to the SEC staff's document requests and inquiries and intends to
continue to cooperate.

RESULTS OF OPERATIONS FOR THE THREE-MONTH PERIOD ENDED SEPTEMBER 30, 2004, AS
COMPARED TO THE THREE-MONTH PERIOD ENDED SEPTEMBER 30, 2003

         NET SALES. For the three months ended September 30, 2004, we had net
sales of $10,467,162, as compared to net sales of $20,220 for the three months
ended September 30, 2003, an increase of $10,446,942. This increase is
attributable to the continuing revenues generated by our subsidiaries, most of
which were acquired in fiscal 2004.

         COST OF GOODS SOLD. For the three months ended September 30, 2004, we
had cost of goods sold of $8,245,298, as compared to cost of goods sold of
$6,904 for the three months ended September 30, 2003, an increase of $8,238,394
or 1193%. This increase is attributable to the operations of our subsidiaries in
2004 for costs incurred in connection with the manufacturing, marketing and
sales of their nutritional supplement products.

                                       17
<PAGE>

         SELLING, GENERAL AND ADMINISTRATIVE EXPENSES. For the three months
ended September 30, 2004, we incurred selling, general and administrative
expenses of $1,282,870 as compared to selling, general and administrative
expenses of $375,731 for the three months ended September 30, 2003, an increase
of $907,139 or 241%. This increase is primarily attributable to the operations
of our subsidiaries. PNLabs, Inc., American Nutritional Exchange, Inc.
Interactive Nutrition International, Inc., Weifang Shengtai Pharmaceuticals
Co., Ltd., ANI Distribution, Inc. and Nutrition Services Corp. and included
employees compensation, rents, utilities, products distribution, insurance,
legal and accounting fees.

         OPERATING INCOME. For the three months ended September 30, 2004, we had
operating income of $938,994, as compared to an operating loss of $362,415 for
the three months ended September 30, 2003, an improvement of $1,301,409 or 359%.
This improvement is attributable to the performance of our subsidiaries, most of
which were acquired during fiscal year 2004.

         NET LOSS. For the three months ended September 30, 2004, we incurred a
net loss of $1,265,003 as compared to a net loss of $367,198 for the three
months ended September 30, 2003, an increase of $897,805 or 245%. This increase
is attributable to the Company recording depreciation and amortization of
$1,273,958, interest expense of $645,039 and reserves for minority interests
totaling $285,000. During the nine months ended September 30, 2004, the Company
issued $15,000,000 of convertible notes with interest at 5%. For the three
months ended September 30, 2004, the Company recorded interest expense of
approximately $645,000 as a result of discounts amortized relating to these
notes. The notes are convertible for a period of 6 months after the effective
date through September, 2004.

RESULTS OF OPERATIONS FOR THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2004, AS
COMPARED TO THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2003

         NET SALES. For the nine months ended September 30, 2004, we had net
sales of $26,068,340, as compared to net sales of $20,220 for the nine months
ended September 30, 2003, an increase of $26,048,120. This increase is
attributable to the continuing revenues generated by out subsidiaries most of
which are acquired in fiscal 2004.

         COST OF GOODS SOLD. For the nine months ended September 30, 2004, we
had cost of goods sold of $19,684,545, as compared to cost of goods sold of
$6,904 for the nine months ended September 30, 2003, an increase of $19,677,641.
This increase is attributable to the operations of our subsidiaries, in 2004 for
costs incurred in connection with the manufacturing, marketing and sales of
their nutritional supplement products.

         SELLING, GENERAL AND ADMINISTRATIVE EXPENSES. For the nine months ended
September 30, 2004, we incurred selling, general and administrative expenses of
$4,336,079, as compared to selling, general and administrative expenses of
$691,659 for the nine months ended September 30, 2003, an increase of $3,644,420
or 527%. This increase is primarily attributable to the operations of our
subsidiaries, PNLabs, Inc., American Nutritional Exchange, Inc., Interactive
Nutrition International, Inc., Weifang Shengtai Pharmaceuticals Co. Ltd., ANI
Distribution, Inc. and Nutritional Sciences Corp. and included employees
compensation, rents, utilities, products distribution, insurance, legal and
accounting fees.

         OPERATING INCOME. For the nine months ended September 30, 2004,
operating income of $2,047,716, as compared to an operating loss of $678,343 for
the nine months ended September 30, 2003, an improvement of $2,726,059 or 402%.
This improvement is attributable to the performance of our subsidiaries, most of
which were acquired during fiscal year 2004.

         NET LOSS. For the nine months ended September 30, 2004, we incurred a
net loss of $6,354,083 as compared to $691,125 for the nine months ended
September 30, 2003, an increase of $5,662,958 or 819%. This increase is
primarily attributable to the Company recording interest expense of
approximately $5,484,841 as a result of the amortization of discounts relating
to a $5 million secured promissory note and a $15 million secured convertible
debenture incurred in 2004, depreciation and amortization of $2,256,958 and
reserves for minority interests totaling $660,000.

LIQUIDITY AND CAPITAL RESOURCES

         As of September 30, 2004, we had cash and other current assets totaling
$16,691,119, as compared to $285,647 as of September 30, 2003. The significant
increase in our cash position is directly attributable to our decision to draw
down a portion of a previous Equity Line of Credit, dated July 25, 2002 with
Cornell Capital Partners, the sale of a Secured Convertible Debenture in the
principal amount of $15 million, each discussed below, and the acquisition of
our subsidiaries.

         As of September 30, 2004, we had approximately $8,559,316 in property
and equipment, as compared to $38,003 as of September 30, 2003. As of September
30, 2004, our total current liabilities were $24,692,296, consisting primarily
of accounts payable and accrued expenses of $6,205,132, current installments of
a note payable of $7,687,094 and a convertible debenture balance of $10,800,000.
As of September 30, 2004 we had a working capital deficit of $8,001,107.

         On March 26, 2004, we entered into a Standby Equity Distribution
Agreement with Cornell Capital Partners. Pursuant to the Standby Equity
Distribution Agreement, we may, at our discretion, periodically issue and sell


                                       18
<PAGE>

shares of our common stock for a total purchase price of $50 million. If we
request advances under the Standby Equity Distribution Agreement, Cornell
Capital Partners will purchase shares of common stock of Bio-One for 100% of the
lowest closing bid price on the Over-the-Counter Bulletin Board or other
principal market on which our common stock is traded for the 5 days immediately
following the advance notice date. Cornell Capital Partners will retain 5% of
each advance under the Standby Equity Distribution Agreement. We may not request
advances in excess of a total of $50 million. The maximum of each advance is
equal to $525,000 and up to a maximum of $2,100,000 in any thirty-day period. As
of September 30, 2004 we have received $10,700,000 under the Standby Equity
Distribution Agreement.

         On February 5, 2004, Bio-One executed a Secured Promissory Note payable
to Cornell Capital Partners in the principal amount of $5,000,000. The Secured
Promissory Note accrued interest at an annual rate of 12% and was payable out of
cash of Bio-One or out of the net proceeds received by Bio-One under our
previous Equity Line of Credit Agreement, dated July 25, 2002, with Cornell
Capital Partners. Bio-One must pay all amounts due under the Promissory Note by
August 3, 2004, regardless of the availability of proceeds under the Equity Line
of Credit. The Promissory Note was secured by all of the assets of Bio-One. As
of June 30, 2004 this Promissory Note had been repaid in full.

         As of March 31, 2004, we issued a Secured Convertible Debenture in the
principal amount of $15 million with Cornell Capital Partners. The convertible
debenture is convertible into shares of our common stock at a price per share
that is equal to the lesser of (i) an amount equal to $0.75 or (ii) an amount
equal to 80% of the average of the lowest daily volume weighted average price of
our common stock for the five trading days immediately preceding the conversion
date. The convertible debenture accrues interest at a rate of 5% per year and is
convertible at the holder's option. The convertible debenture has a term of 7
months and is secured by the assets of Bio-One and a second position security
interest in the assets of Interactive Nutrition Inc. At Bio-One's option, the
convertible debenture may be paid in cash or converted into shares of our common
stock unless converted earlier by the holder. The original payment terms were
$1,000,000 per week for five weeks commencing after May 1, 2004, resuming after
July 1, 2004 and after September 1, 2004. These payment terms have been extended
through an oral agreement with Cornell Capital Partners. Except after an event
of default, as set forth in the Secured Convertible Debenture the holder shall
not be entitled to convert such debenture for a number of shares of common stock
of Bio-One in excess of that number of shares which, upon giving effect to such
conversion, would cause the aggregate number of shares of common stock
beneficially held by such holder and its affiliates to exceed 4.99% of the
outstanding shares of common stock of Bio-One. As of November 1, 2004 $4.2
million had been repaid through proceeds under the Standby Equity Distribution
Agreement.

         As of September 30, 2004, we estimate that during the next twelve
months we will require $1,000,000 to fund our current subsidiaries development,
$1,800,000 to fund our anticipated corporate operating expenses, and
approximately $15,000,000 to fund our expansion plans. On October 15, 2004
Bio-One signed a term sheet for a secured revolving credit and term loan
facility of up to $15,000,000 to be used to repay existing indebtedness and for
future working capital purposes. On October 9, 2004 Bio-One signed a term sheet
for a $10 million mezzanine credit facility in connection with our proposed
acquisition of certain business targets and the expansion of the business and
working capital. We are currently in the due diligence phase with each, and if
approved, would lead to a closing of both transactions prior to December 31,
2004. Both of the credit facilities would be secured by a first and second
priority lien on all existing and future assets of Bio-One.

         As of November 1, we believe we have sufficient cash to operate for
approximately three to six months.

CERTAIN BUSINESS RISK FACTORS

         We are subject to various risks, which may have a material adverse
effect on our Company's business, financial condition and results of operations.
Certain risks are discussed below:

WE HAVE HISTORICALLY LOST MONEY AND LOSSES MAY CONTINUE IN THE FUTURE

         We have a history of losses. We have incurred an operating loss since
inception and had an accumulated deficit of $3,258,984 as of December 31, 2003.
For the years ended December 31, 2003, 2002 and 2001, we incurred a net loss of
$1,383,112, $609,761 and $677,150, respectively. For the nine months ended
September 30, 2004, we incurred a net loss of $6,354,083. We cannot predict the
amount of revenues we may generate as a result of our recent acquisitions.
Consequently, we will in all likelihood, have to rely on external financing for
our capital requirements. Future losses may occur unless we continue to
successfully implement our business plan, which calls for us to secure both debt
and equity financing while continuing to aggressively pursue acquisitions and/or
joint ventures with companies in the nutritional supplement industry. If we are
not successful in maintaining profitable operations, we may not be able to
attract sufficient capital to fully continue our operations. Our inability to
obtain adequate financing could result in the need to curtail or cease business
operations and would likely result in a lower stock price.

WE WILL NEED TO RAISE ADDITIONAL CAPITAL TO FINANCE OPERATIONS

         We have relied on significant external financing to fund our
operations. As of September 30, 2004, we had received a total of $6.5 million
under our previously existing Equity Line of Credit that we entered into July
25, 2002 with Cornell Capital Partners. We received these proceeds in fiscal
years 2002, 2003 and 2004. As of September 30, 2004, we had received a total of
$4.2 million under our new SEDA. Prior to our previously existing Equity Line of
Credit, our officers and directors advanced us approximately $70,000 in 2002
during a period in which we had approximately $20,000 in revenues. As of
September 30, 2004, we had $1,200,198 in cash and cash equivalents and our total
current assets were $16,691,119. Our current liabilities were $24,692,226 as of
September 30, 2004. We will need to raise additional capital to fund our
anticipated business development and future acquisitions. Unless we continue
profitable operations, it is unlikely that we will be able to secure additional
financing from external sources. As of September 30, 2004, we estimate that


                                       19
<PAGE>

during the next 12 months we will require $2,000,000 to fund our anticipated
corporate operating expenses, $1,000,000 to fund certain subsidiaries
development and approximately $15,000,000 to fund our acquisitions plans. The
sale of our common stock to raise capital may cause dilution to our existing
shareholders. Our inability to obtain adequate financing could result in the
need to limit business operations. Any of these events could be materially
harmful to our business and may result in a lower stock price. Our inability to
obtain adequate financing could result in the need to curtail business
operations and you could lose your entire investment. Our financial statements
do not include any adjustments that might result from the outcome of this
uncertainty.

WE CANNOT PREDICT THE OUTCOME OF THE SEC INQUIRY

         The Company has received requests from the SEC's Division of
Enforcement for certain documents and information, including documents regarding
recent and prospective acquisitions and business arrangements with certain
companies, prospective investors, recent issuances of Company securities, and
financial statements with respect to recent acquisitions. The Company is
responding to the SEC staff's document requests and inquiries and intends to
continue to cooperate. However, the Company cannot predict the duration or
outcome of the SEC's inquiry or whether the inquiry will have a material,
adverse effect on the Company and its business plan.

WE MAY NOT BE SUCCESSFUL IN INTEGRATING THE BUSINESSES OF OUR 2004 ACQUISITIONS

         On September 11, 2003, our wholly-owned subsidiary, PNLabs, Inc.,
acquired substantially all of the assets of Physicians Nutraceutical
Laboratories, Inc. The purchased assets included, among other things, the rights
to market the 5 products marketed by Physicians Nutraceutical Laboratories and
all rights to the operational business of Physicians Nutraceutical Laboratories.
On February 4, 2004, we acquired shares of American Nutritional Exchange, Inc.
representing 80% of the votes of all issued and outstanding shares of American
Nutritional Exchange. American Nutritional Exchange is a wholesale distributor
of nationally branded nutritional supplements. On March 31, 2004, we acquired
all of the issued and outstanding capital stock of Interactive Nutrition, Inc.
Interactive Nutritional is a manufacturer and distributor of branded, specialty
nutritional supplements, which are currently marketed in the United States,
Canada and Hong Kong. On April 4, 2004, we acquired a 51% interest in Weifang
Shengtai Pharmaceuticals Co. Ltd., a Chinese joint venture. Weifang Shengtai
Pharmaceuticals is a manufacturer and distributor of glucose in China. In April
2004, we formed Nutrition Sciences Corporation, in which we own 80% of the
issued and outstanding capital stock. Nutrition Sciences was formed to provide
direct mail solutions to our portfolio companies, sell its own products and be a
vendor of direct mail solutions to independent clients. On April 15, 2004 we
formed ANI Distribution, Inc. in which we own 51% of the issued and outstanding
capital stock. ANI Distribution was formed to acquire distributors of
nutritional supplements and related products in areas outside of the
distribution area of American Nutritional Exchange. On July 20, 2004, ANI
Distribution acquired the assets of Florida Sport Distributors, Inc., a
wholesale distributor of nationally branded nutritional supplements. On June 10,
2004 we formed Healthy Choices Concepts, in which we own all of the issued and
outstanding shares of capital stock. Healthy Choices Concepts was formed to
provide infomercial and direct to consumer solutions to our portfolio companies,
sell its own products and be a vendor of infomercial and direct to consumer
solutions to independent clients.

         We may fail to successfully market our products and/or integrate the
operations of Physicians Nutraceutical Laboratories, American Nutritional
Exchange, Interactive Nutrition, Weifang Shengtai Pharmaceuticals, Nutrition
Sciences, ANI Distribution or Healthy Choices Concepts. The integration of our
new operations could place an increasing strain on our management and financial
resources

OUR COMMON STOCK MAY BE AFFECTED BY LIMITED TRADING VOLUME AND MAY FLUCTUATE
SIGNIFICANTLY

         Our common stock is traded on the Over-the-Counter Bulletin Board.
Prior to this offering, there has been a limited public market for our common
stock and there can be no assurance that an active trading market for our common
stock will develop. As a result, this could adversely affect our shareholders'
ability to sell our common stock in short time periods, or possibly at all. Our
common stock is thinly traded compared to larger, more widely known companies in
the nutritional supplement industry. Thinly traded common stock can be more
volatile than common stock traded in an active public market. The average daily
trading volume of our common stock in September 2004 was 3,540,968 shares. The
high and low bid price of our common stock for the last two years has been $0.40
and $0.03, respectively. Our common stock has experienced, and is likely to
experience in the future, significant price and volume fluctuations, which could
adversely affect the market price of our common stock without regard to our
operating performance. In addition, we believe that factors such as quarterly
fluctuations in our financial results and changes in the overall economy or the
condition of the financial markets could cause the price of our common stock to
fluctuate substantially.

WE MAY NOT BE ABLE TO ACCESS SUFFICIENT FUNDS WHEN NEEDED THROUGH DEBT, EQUITY
OR UNDER THE STANDBY EQUITY DISTRIBUTION AGREEMENT AND THE PRICE OF OUR COMMON
STOCK MAY AFFECT OUR ABILITY TO DRAW DOWN ON THE STANDBY EQUITY DISTRIBUTION
AGREEMENT

         Currently, we are dependent upon external financing to fund the future
development of our operations. Our financing needs are expected to be provided
through debt, equity or by our Standby Equity Distribution Agreement. The amount
of each advance under the Standby Equity Distribution Agreement is subject to a
maximum amount equal to $525,000 and up to an aggregate maximum advance amount
equal to $2,100,000 in any thirty-calendar-day period. Because of this maximum
advance restriction, we may not be able to access sufficient funds when needed.

                                       20
<PAGE>

         In addition, there is an inverse relationship between the price of our
common stock and the number of shares of common stock which will be issued under
the Standby Equity Distribution Agreement. Based on our recent stock price of
$0.04, we would have to issue to Cornell Capital Partners more shares of our
common stock than we have authorized in order to draw down the entire $50
million available to us under the Standby Equity Distribution Agreement. We
registered 250,000,000 shares of our common stock under the Standby Equity
Distribution Agreement in a registration statement on Form SB-2 that was
declared effective by the Securities and Exchange Commission on May 11, 2004.
Our Articles of Incorporation currently authorize Bio-One to issue 500 million
shares and, as of September 30, 2004, we had 165,003,173 shares of common stock
issued and outstanding. In the event we desire to draw down any available
amounts remaining under the Standby Equity Distribution Agreement after we have
issued the 250,000,000 shares that were registered with the Securities and
Exchange Commission, we will have to file a new registration statement to cover
such additional shares that we would issue for additional draw downs on the
Standby Equity Distribution Agreement. Unless we maintain profitable operations,
it is unlikely that we will be able to secure additional financing from external
sources other than our Standby Equity Distribution Agreement. Therefore, if we
are unable to draw down on our Standby Equity Distribution Agreement, we may be
forced to limit the development of our business operations.

OUR COMMON STOCK IS DEEMED TO BE "PENNY STOCK," WHICH MAY MAKE IT MORE DIFFICULT
FOR INVESTORS TO SELL THEIR SHARES DUE TO SUITABILITY REQUIREMENTS

         Our common stock is deemed to be "penny stock" as that term is defined
in Rule 3a51-1 promulgated under the Securities Exchange Act of 1934. Penny
stocks are stock:

         o        With a price of less than $5.00 per share;

         o        That are not traded on a "recognized" national exchange;

         o        Whose prices are not quoted on the NASDAQ automated quotation
                  system (NASDAQ listed stock must still have a price of not
                  less than $5.00 per share); or

         o        In issuers with net tangible assets less than $2.0 million (if
                  the issuer has been in continuous operation for at least three
                  years) or $5.0 million (if in continuous operation for less
                  than three years), or with average revenues of less than $6.0
                  million for the last three years.

         Broker/dealers dealing in penny stocks are required to provide
potential investors with a document disclosing the risks of penny stocks.
Moreover, broker/dealers are required to determine whether an investment in a
penny stock is a suitable investment for a prospective investor. These
requirements may reduce the potential market for our common stock by reducing
the number of potential investors. This may make it more difficult for investors
in our common stock to sell shares to third parties or to otherwise dispose of
them. This could cause our stock price to decline.

WE COULD FAIL TO CONTINUE TO ATTRACT OR RETAIN KEY PERSONNEL

         Our success largely depends on the efforts and abilities of Armand
Dauplaise, our President and Chief Executive Officer, Bob Ramsey our Vice
President of Operations and Bernard Shinder our Chief Financial Officer. Mr.
Dauplaise and Mr. Shinder have been instrumental in securing our existing
financing arrangements. In addition, Mr. Dauplaise's efforts resulted in the
consummation of our recent acquisitions. Mr. Dauplaise is also primarily
responsible for identifying additional acquisition candidates with the
assistance of Health Business Partners LLC and undertaking due-diligence
investigations. Mr. Dauplaise receives a salary of $240,000 per year and a car
allowance pursuant to his employment agreement with Bio-One. The employment
agreement is for one year and is renewable annually. The loss of the services of
Mr. Dauplaise could materially harm our business because of the cost and time
necessary to recruit and train a replacement. Such a loss would also divert
management attention away from operational issues. We do not presently maintain
a key-man life insurance policy on Mr. Dauplaise. Mr. Ramsey receives a salary
of $150,000 per year. Mr. Shinder receives compensation of $180,000 per year. In
addition, in order to continue to implement our business strategy, we believe
that we will need to attract and retain a Director of Marketing, an Information
Technology Officer and additional administrative support staff as our company
grows.

                                       21
<PAGE>

WE MAY BE UNABLE TO MANAGE GROWTH

         Successful implementation of our business strategy requires us to
manage our growth. Growth could place an increasing strain on our management and
financial resources. To manage growth effectively, we will need to:

         o        Respond to the needs of an operating business and be able to
                  continue integrating management and controls with our recent
                  acquisitions; and

         o        Attract and retain qualified personnel, as well as, develop,
                  train and supervise management-level and other employees.

         If we fail to manage our growth effectively, our business, financial
condition or operating results could be materially harmed, and our stock price
may decline.

THE ISSUANCE OF PREFERRED STOCK MAY ENTRENCH MANAGEMENT OR DISCOURAGE A CHANGE
OF CONTROL

         Our Articles of Incorporation authorizes the issuance of up to
10,000,000 shares of preferred stock with designations rights, and preferences
determined from time to time by our Board of Directors. Accordingly, our Board
of Directors is empowered, without stockholder approval, to issue preferred
stock with dividends, liquidation, conversion, voting, or other rights that
could adversely affect the voting power or other rights of the holders of our
common stock. In the event of issuance, the preferred stock could be used, under
certain circumstances, as a method of discouraging, delaying or preventing a
change in control of the company or, alternatively, granting the holders of
preferred stock such rights as to entrench management. We currently have
2,090,000 shares of Series A Preferred Stock outstanding. On September 30, 2004,
we filed a definitive proxy statement asking shareholders to vote on several
proposals, including a proposal to amend our Articles of Incorporation to
increase the authorized preferred stock of Bio-One to 50,000,000. If the holders
of our common stock desired to remove current management, it is possible that
our Board of Directors could issue preferred stock and grant the holders thereof
such rights and preferences so as to discourage or frustrate attempts by the
common stockholders to remove current management. In doing so, management would
be able to severely limit the rights of common stockholders to elect the Board
of Directors.

WE EXPECT INTENSE COMPETITION IN OUR INDUSTRY

         Many of our competitors have significantly greater name recognition and
financial and other resources. If we are not able to compete effectively against
our competitors, we will be forced to curtail or cease our business operations.
Our main competitors are NBTY, Natrol, Herbalife and Nutraceuticals. We believe
the products that compete with ours, include Cholesterol Success, Cholesterol
Free Fish Oil, Complete Balance, Dong Quai, Arthritis Pain Relief and Bone Core,
Centrum and ABC Plus. Our market share in the nutrition supplement industry is
very small at this time.

OUR INDUSTRY IS SUBJECT TO GOVERNMENT REGULATION

         The manufacturing, processing, formulation, packaging, labeling and
advertising of vitamins and other nutritional products are subject to regulation
by one or more federal agencies, including the Food and Drug Administration, the
Federal Trade Commission, the Consumer Product Safety Commission, the United
States Department of Agriculture, the United States Postal Service, the United
States Environmental Protection Agency and the Occupational Safety and Health
Administration. Our operations are subject to governmental regulation in the
jurisdictions in which they operate. These activities are also regulated by
various agencies of the states and localities, as well as of foreign countries,
in which our products may be sold. We may incur significant costs in complying
with these regulations. In the event we cannot comply with government
regulations affecting our business and products, we may be forced to curtail or
cease our business operations.

FUTURE ACQUISITIONS MAY DISRUPT OUR BUSINESS AND DEPLETE OUR FINANCIAL RESOURCES

         Any future acquisitions we make could disrupt our business and
seriously harm our financial condition. We intend to consider investments in
complementary companies, products and technologies. We anticipate buying
businesses, products and/or technologies in the future in order to fully
implement our business strategy. In the event of any future acquisitions, we
may:

         o        issue stock that would dilute our current stockholders'
                  percentage ownership;

         o        incur debt;

         o        assume liabilities;

         o        incur amortization expenses related to goodwill and other
                  intangible assets; or

         o        incur large and immediate write-offs.

                                       22
<PAGE>

         The use of debt or leverage to finance our future acquisitions should
allow us to make acquisitions with an amount of cash in excess of what may be
currently available to us. If we use debt to leverage up our assets, we may not
be able to meet our debt obligations if our internal projections are incorrect
or if there is a market downturn. This may result in a default and the loss in
foreclosure proceedings of the acquired business or the possible bankruptcy of
our business.

         Our operation of any acquired business will also involve numerous
risks, including:

         o        integration of the operations of the acquired business and its
                  technologies or products;

         o        unanticipated costs;

         o        diversion of management's attention from our core business;

         o        adverse effects on existing business relationships with
                  suppliers and customers;

         o        risks associated with entering markets in which we have
                  limited prior experience; and

         o        potential loss of key employees, particularly those of the
                  purchased organizations.

OUR STANDBY EQUITY DISTRIBUTION AGREEMENT COULD HAVE AN ADVERSE EFFECT ON OUR
ABILITY TO MAKE ACQUISITIONS WITH OUR COMMON STOCK

         We cannot predict the actual number of shares of common stock that will
be issued pursuant to our Standby Equity Distribution Agreement, in part,
because the purchase price of the shares will fluctuate based on prevailing
market conditions and we have not determined the total amount of advances we
intend to draw. It may be necessary for our shareholders to approve an increase
in our authorized common stock for us to register additional shares of common
stock in order to have sufficient authorized shares available to make
acquisitions using our common stock. As we issue shares of common stock pursuant
to the Standby Equity Distribution Agreement, we may not have sufficient shares
of our common stock available to successfully attract and consummate future
acquisitions.

INVESTORS SHOULD NOT RELY ON AN INVESTMENT IN OUR STOCK FOR THE PAYMENT OF CASH
DIVIDENDS

         We have not paid any cash dividends on our capital stock and we do not
anticipate paying cash dividends in the future. Investors should not make an
investment in our common stock if they require dividend income. Any return on an
investment in our common stock will be as a result of any appreciation, if any,
in our stock price.

THERE ARE NO CONCLUSIVE STUDIES REGARDING THE MEDICAL BENEFITS OF NUTRITIONAL
SUPPLEMENTS

         Many of the ingredients in our current products, and we anticipate in
our future products, will be vitamins, minerals, herbs and other substances for
which there is not a long history of human consumption. Although we believe all
of our products to be safe when taken as directed by us, there is little
experience with human consumption of certain of these product ingredients in
concentrated form. In addition, we are highly dependent upon consumers'
perception of the safety and quality of our products as well as similar products
distributed by other companies, we could be adversely affected in the event any
of our products or any similar products distributed by other companies should
prove or be asserted to be harmful to consumers. In addition, because of our
dependence upon consumer perceptions, adverse publicity associated with illness
or other adverse effects resulting from consumers' failure to consume our
products as we suggest or other misuse or abuse of our products or any similar
products distributed by other companies could have a material adverse effect on
the results of our operations and financial condition.

THE MANUFACTURE AND DISTRIBUTION OF VITAMINS AND OTHER NUTRITIONAL SUPPLEMENTS
COULD RESULT IN PRODUCT LIABILITY CLAIMS

         We, like any other retailer, distributor and manufacturer of products
that are designed to be ingested, face an inherent risk of exposure to product
liability claims in the event that the use of our products results in injury.
Such claims may include, among others, that our products contain contaminants or
include inadequate instructions as to use or inadequate warnings concerning side
effects and interactions with other substances. We do not anticipate obtaining


                                       23
<PAGE>

contractual indemnification from parties supplying raw materials or marketing
our products. In any event, any such indemnification if obtained will be limited
by our terms and, as a practical matter, to the creditworthiness of the
indemnifying party. In the event that we do not have adequate insurance or
contractual indemnification, product liabilities relating to defective products
could have a material adverse effect on our operations and financial conditions.
Our subsidiaries currently have product liability insurance in the amount of
$2,000,000 or more. Our current product liability insurance may not be adequate
to protect us in the event of a claim. In the event our insurance is not
adequate, we could be forced to curtail or cease our business operations.

POTENTIAL EFFECT OF ADVERSE PUBLICITY

         We believe the growth experienced by the nutritional supplement market
is based in part on national media attention regarding scientific research
suggesting potential health benefits from regular consumption of certain
vitamins and other nutritional products. Such research has been described in
major medical journals, magazines, newspapers and television programs. The
scientific research to date is preliminary.

         In the future, scientific research and/or publicity may not be
favorable to the nutritional supplement market or any particular product, or may
be inconsistent with earlier favorable research or publicity. Future reports of
research that are perceived as less favorable or that question such earlier
research could have a material adverse effect on our operations and financial
condition. Because of our dependence upon consumer perceptions, adverse
publicity associated with illness or other adverse effects resulting from the
consumption of our products or any similar products distributed by other
companies could have a material adverse effect on our operations. Such adverse
publicity could arise even if the adverse effects associated with such products
resulted from consumers' failure to consume such products as directed. In
addition, we may not be able to counter the effects of negative publicity
concerning the efficacy of our products. Any such occurrence could have a
negative effect on our operations.

ANY FUTURE ACQUISITIONS MAY HAVE TO DEVELOP NEW PRODUCTS IN ORDER TO KEEP PACE
WITH CHANGING CONSUMER DEMANDS

         The nutritional supplement industry is highly competitive and
characterized by changing consumer preferences and continuous introduction of
new products. Our goal is to expand our portfolio of nutritional supplement
products through acquisition of existing companies and/or products serving niche
segments of the industry. New products may be introduced in a timely and regular
basis to maintain distributor and consumer interest and appeal to varying
consumer preferences.

         We believe that any future success of our company will depend, in part,
on our ability to anticipate changes in consumer preferences and acquire,
manage, develop and introduce, in a timely manner, new products that adequately
address such changes. If we are unable to develop and introduce new products or
if our new products are not successful, our sales may be adversely affected as
customers seek competitive products. In addition, our introduction or our
announcement of new products could result in a reduction in sales of our
existing products, requiring us to carefully manage product introductions in
order to minimize disruption in sales of our existing products. Any reduction in
purchases or consumption of our existing products could have a material adverse
effect on our business, operating results and financial condition.

ITEM 3.  CONTROLS AND PROCEDURES

         EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES. Within 90 days prior
to the filing date of this report, the Company carried out an evaluation of the
effectiveness of the design and operation of its disclosure controls and
procedures pursuant to Exchange Act Rule 13a-14. This evaluation was done under
the supervision and with the participation of the Company's President and Chief
Financial Officer. Based upon that evaluation, they concluded that the Company's
disclosure controls and procedures are effective in gathering, analyzing and
disclosing information needed to satisfy the Company's disclosure obligations
under the Exchange Act.

         CHANGES IN INTERNAL CONTROLS. There were no significant changes in the
Company's internal controls or in other factors that could significantly affect
those controls since the most recent evaluation of such controls.

                                       24
<PAGE>

                                     PART II


                                OTHER INFORMATION


ITEM 1.  LEGAL PROCEEDINGS

         We are not aware of any legal proceedings involving our Company.


ITEM 2.  CHANGES IN SECURITIES AND USE OF PROCEEDS

         (a) None.

         (b) None.

         (c) None.

         With respect to the sale of unregistered securities referenced above,
all transactions were exempt from registration pursuant to Section 4(2) of the
Securities Act of 1933 (the "1933 Act"), and Regulation D promulgated under the
1933 Act. In each instance, the purchaser had access to sufficient information
regarding Bio-One so as to make an informed investment decision. More
specifically, Bio-One had a reasonable basis to believe that each purchaser was
an "accredited investor" as defined in Regulation D of the 1933 Act and
otherwise had the requisite sophistication to make an investment in Bio-One's
common stock.

         (d) None.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

         Not applicable.


ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

         Not applicable.


ITEM 5.  OTHER INFORMATION

         Not applicable.


                                       25
<PAGE>

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

         (A)      EXHIBITS.
<TABLE>
<CAPTION>

EXHIBIT NO.        DESCRIPTION                                          LOCATION
-----------        -----------                                          --------
<S>                <C>                                                  <C>
3.(i).1            Articles of Incorporation of Bio-One Corporation     Incorporated by reference to the Company's
                   filed February 24, 1998                              Registration Statement filed on Form 10-SB filed
                                                                        November 3, 2000

3.(i).2            Certificate of Amendment of Articles of              Incorporated by reference to the Company's
                   Incorporation filed August 7, 2000                   Registration Statement filed on Form 10-SB filed
                                                                        November 3, 2000

3.(ii).1           Bylaws of Bio-One Corporation                        Incorporated by reference to the Company's
                                                                        Registration Statement filed on Form 10-SB filed
                                                                        November 3, 2000

10.1               Share Exchange Agreement between the Company and     Incorporated by reference to the Company's
                   Crown Enterprises dated May 20, 2000                 Registration Statement filed on Form 10-SB filed
                                                                        November 3, 2000

10.2               Employment Agreement between the Company and         Incorporated by reference to the Company's
                   Armand Dauplaise dated May 30, 2000                  Registration Statement filed on Form 10-SB filed
                                                                        November 3, 2000

10.3               Equity Line of Credit Agreement between the          Incorporated by reference to the Company's
                   Company and Capital Partners, LP dated July 25,      Quarterly report filed on Firm 10-QSB for the
                   2002                                                 period ended June 30, 2002 on August 14, 2002

10.4               Placement Agent Agreement between Bio-One Corp and   Incorporated by reference to the Company's Form
                   Westrock Advisors                                    SB-2 Registration Statement filed August 27, 2002

10.5               Registration Rights Agreement between Bio-One        Incorporated by reference to the Company's Form
                   Corporation and Cornell Capital Partners, LLP        SB-2 Registration Statement filed August 27, 2002

10.6               Escrow Agreement between Bio-One Corporation,        Incorporated by reference to the Company's Form
                   Cornell Capital Partners, L.P. Butler Gonzales LLP   SB-2 Registration Statement filed August 27, 2002
                   and Wachovia Bank, N.A.

10.7               Agreement between the Company and Kevin Lockhart     Incorporated by reference to the Company's
                   and General Release in connection with redemption    Form 8-K filed August 2, 2002
                   of shares and resignation as Board Member

31.1               Certification Pursuant to Section 302                Provided herewith

31.2               Certification Pursuant to Section 302                Provided herewith

32.1               Certification Pursuant to 18 U.S.C. Section 1350     Provided herewith

32.2               Certification Pursuant to 18 U.S.C. Section 1350     Provided herewith

</TABLE>

                                       26
<PAGE>

         (B)      REPORTS ON FORM 8-K.

         On November 2, 2004, the Company filed an amendment to a Current
Report on Form 8-K with respect to Items 2.01 and 9.01, respectively.

         On November 3, 2003, the Company filed an amendment to a Current Report
on Form 8-K with respect to Items 2.01 and 9.01, respectively.

         On November 5, 2004, the Company filed an amendment to a Current Report
on Form 8-K with respect to Items 2.01 and 9.01, respectively.



                                       27
<PAGE>



                                   SIGNATURES

         In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

Date:  November 12, 2004          BIO-ONE CORPORATION

                                   By:  /s/ Armand Dauplaise
                                        --------------------
                                        Armand Dauplaise
                                        President, Chief Executive Officer,
                                        Chief Financial Officer and
                                        Principal Accounting Officer











                                       28